Lead Product(s) : Gallium Maltolate
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
IQ-AI Announces Orphan Drug Designation for GaM in Pediatric GBM
Details : Gallium maltolate is a orally administered drug is investigated for the treatment of pediatric glioblastoma multiforme patients and received Orphan Drug Designation from FDA.
Brand Name : GaM
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 13, 2023
Lead Product(s) : Gallium Maltolate
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Gallium Maltolate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : IQ-AI
Deal Size : Not Applicable
Deal Type : Not Applicable
IQ-AI Announces Orphan Drug Designation Status
Details : Gallium Maltolate (GaM) is the oral agent under study in IQAI's sponsored Phase I clinical trial being conducted at the Medical College of Wisconsin for the treatment of glioblastoma multiforme (GBM) brain cancer.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 28, 2023
Lead Product(s) : Gallium Maltolate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : IQ-AI
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?